Jazz Pharmaceuticals plc
JAZZHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The $14.19B market capitalization puts JAZZ squarely in large-cap range for its industry. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Market Cap
$14.19B
Beta
0.27
P/E (TTM)
2055.64
P/E (Fwd)
8.79
EPS (TTM)
$0.11
EPS (Fwd)
$25.73
ROE
0.7%
ROA
6.9%
Cash
$2.87B
Total Debt
$5.42B
Free CF
$1.34B
52W Change
106.6%
Annual Financials
Cash vs Debt
The company holds $2.87B in cash, though total debt stands at $5.42B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $1.34B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 0.7% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $3.66B to $4.27B.
With a beta below 0.7, Jazz Pharmaceuticals plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. At over 50x earnings, JAZZ carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing JAZZ.